Abstract Cancer is a major burden on populations and health systems internationally. The development of innovative cancer medicines is seen as a significant part of the solution. These new cancer medicines are, however, expensive, leading to limited or delayed access and disagreements among stakeholders about which medicines to fund. There is no obvious resolution to these disagreements, with stakeholders holding firmly to divergent positions. Access to cancer medicines was recently explored in Australia in a Senate Inquiry into the Availability of New, Innovative, and Specialist Cancer Drugs in Australia. We analysed the resultant Senate Report to identify competing stakeholder values. Our analysis illustrates that there are four main Bgoods^prioritized by different stakeholders: 1) innovation, 2) compassion, 3) equity, and 4) sustainability. We observe that, with the exception of sustainability, all of these Bgoods^put pressure on payers to provide access to cancer medicines more quickly and based on less rigorous evaluation processes. We then explore the consequences of giving in to such pressure and suggest that deconstructing the implicit values in calls for Benhanced access^to cancer medicines is necessary so that more nuanced solutions to the challenge of providing access to these high cost medicines can be found.
Introduction
Cancer is a major burden on populations and health systems internationally. Worldwide, cancer is estimated to lead to over eight million deaths per year (approximately 13 per cent of all deaths) and spending on cancer drugs globally has reached over $100 billion per year (World Health Organization 2016; Ghinea, Lipworth, and Kerridge 2016) . The economic burden of cancer is likely to get worse as the incidence of cancer continues to rise, more cancers are diagnosed, and new cancer medicines continue to emerge from the drug development pipeline (which currently includes almost eight hundred different cancer drugs and vaccines [PhRMA 2014] ). New cancer therapies-particularly Btargeted therapies,^which are designed to interfere with specific molecules involved in the growth and progression of cancer-can cost well over $100,000 for a course of treatment (Olver 2015; Dunlevy 2015) , and in some cases a survival advantage of 1.2 months can cost as much as $80,000 (Fojo and Grady 2009 ).
While there is enormous hope attached to emerging cancer therapies, we have now reached a point at which many of these medicines are accessible to only the wealthiest individuals or health systems-a situation that is viewed by many as being both morally and politically untenable. This has led to heated debates about how cancer drug funding should be reformed-debates that have, in turn, revealed a wide variety of views as to what the problem is, and how it should be addressed.
On the one hand, the problem has been framed as one stemming from greater nuance in the classification of cancers and understanding of cancer biology. This has permitted the development of Btargeted^therapies that challenge traditional methods for evaluating medicines (Gibson, Raziee, and Lemmens 2015; European Commission Health Research Directorate 2010; Skerritt 2015) . It is argued that the corresponding fragmentation of pharmaceutical markets into niche diseases or disease subtypes has forced a migration away from the traditional Bblockbuster^model of drug development, where drugs are developed for diseases that affect a large number of people and therefore can be sold relatively cheaply, towards a model where drugs are developed for diseases that target fewer people and as a result, need to be much more expensive per unit in order to be profitable (Gibson, Raziee, and Lemmens 2015; Doglin 2010; Trusheim, Brendt, and Douglas 2007) . Pharmaceutical companies tend to take this view of the Bproblem,^and have become increasingly critical of regulators and public and private insurers (henceforth Bpayers^) for not recognizing, and responding appropriately, to the demands of a shifting technological and pharmaceutical market landscape (Towers 2015; Rappeport and Kirchgaessner 2011) . They have also argued that calls to link drug prices to concrete drug development costs ignore the need to provide a financial incentive to attract investment into a highly competitive, risky, and increasingly fragmented market (Schoonveld 2016) .
Others view the situation differently. They question the high prices being demanded for many cancer drugs-particularly given the fact that many of the newer, and most expensive, cancer medicines offer only marginal benefits (Fojo and Grady 2009; Experts in Chronic Myeloid Leukemia 2013; Kantarijian et al. 2013; Fojo, Mailankody, and Lo 2014) . Evidence from the United States suggests that launch prices for cancer medicines have steadily increased at 10 per cent per annum over eighteen years (after adjusting for inflation and health benefits) (Howard et al. 2015) , while others have found that the cost of manufacturing some new cancer medicines is a tiny fraction of the prices being demanded by companies (Hill et al. 2016 ). In the United States, where prices for medicines are generally highest, there have been calls to pass legislation that will make development and manufacturing costs more transparent and provide those subsidizing medicines with greater power to negotiate prices (Silverman 2015; Morgan 2015) -a view recently supported by the American College of Physicians in their position statement on the matter (Daniel 2016) . Experts have argued that such interventions are necessary as market economics fails to address the problem of Bextremely high launch prices for arguably high-value new products without close competitors^ (Conti and Rosenthal 2016, 706) .
Oncologists themselves have begun to question the high price of cancer medicines. For example, a group of experts in Chronic Myeloid Leukaemia criticized the three-fold price rise of imatinib (Gleevec) over ten years despite all research and development being accounted for in the original price, new indications being developed, and the market increasing dramatically over this time (Experts in Chronic Myeloid Leukemia 2013). Some commentators have recently been critical of the fact that patient advocacy groups tend to demand access to medicines but are silent about prices (Mulcahy 2016) . A group of over one hundred oncologists from the United States argue that hospitals, physicians, drug companies and insurance companies, medicine distributors, and some patient advocacy groups are financially conflicted when it comes to discussing access to cancer drugs and have called on oncologists and patients to advocate for more rational pricing as a fundamental part of the access debate (Tefferi et al. 2015) . No doubt this is a response to increasing awareness that industry mobilizes media and other stakeholders to pressure governments to fund expensive cancer medicines (Booth et al. 2007; MacKenzie et al. 2008) .
Concerns about the high prices of many cancer medicines have been buttressed by increasing recognition that, while a few new cancer medicines have been genuinely revolutionary (e.g. Gleevec for leukaemia), others have far more marginal benefits. A recent Australian study by Lichtenberg, for example, has demonstrated that over twenty-one years, new cancer medicines have only been responsible for a 5 per cent improvement in five-year relative survival-a tiny fraction of the increase in spending on this class of medicines (Lichtenberg 2015) . Another study demonstrated that 70 per cent of cancer medicines approved by the FDA between January 2008 and December 2012 were approved on the basis of surrogate end-points, and 85 per cent of these had not demonstrated improvement in overall survival after several years of follow-up (Kim and Prasad 2015) . Therefore, while pharmaceutical companies, as well as some physicians and cancer patients, accuse payers of not providing affordable access to new and potentially beneficial cancer medicines, others target their discontent at pharmaceutical companies for what they perceive to be inexplicable pricing models and arbitrary price hikes.
At present, there is no obvious way through these debates, with people on both Bsides^holding rigidly to their views about the causes of, and solutions to, problems with cancer drug funding. One way to make debates of this kind more nuanced and to make stakeholders more receptive to alternative views is to examine in detail the values underpinning the various positions that are being taken. With this in mind, we deconstructed a recent debate about access to innovative cancer medicines in Australia, in order to elicit the various ways in which stakeholders conceptualized Bthe good^in relation to medicines resource allocation. We did so on the assumption that arguments about the Bright^way to organize health systems are underpinned by more fundamental ideas about Bthe good^-a view taken by, for example, the late health economist Gavin Mooney, who argued that B … until it is known what the good of health care is there cannot be a judgement about what is better, and … until it is known what is better there cannot be a judgement about what is quality ( Mooney 2000a, 1) .
We accept that the Australian context has a number of characteristics that distinguish it from many other systems: it represents a mixture of private medicine and a tax-subsidized system of healthcare to which everyone has access; its native pharmaceutical industry is small, and it relies greatly on imported drugs; its research is active, but capacity for local development is limited; there is a traditional public support for special services in health; it serves a relatively small population (24 million); and outright poverty is relatively uncommon, although there are increasing margins opening between rich and poor. These, and other factors such as geography of the land-mass and relative isolation, make the details of the Australian problem peculiar to Australia. Nevertheless, language, tradition, trade and educational relationships, and political alignments make for understanding and similarity of discourse, particularly among Anglophone countries with sophisticated health technology assessment processes.
Our paper is organized as follows: we first present a summary of the process by which Australian patients gain access to cancer medicines and introduce the recent Australian Senate Report into the Availability of New, Innovative, and Specialist Cancer Drugs in Australia (Senate Community Affairs Reference Committee 2015). We then analyse the report, with a focus on deconstructing the values and the justificatory arguments of the various groups involved, and we conclude by interpreting and discussing the practical implications of our findings to the Australia context.
Access to Cancer Medicines in Australia
In Australia, decisions about funding medicines, including cancer medicines, are made at a number of levels, including by government, hospitals, private insurers, and pharmaceutical companies. At the Federal level, the Pharmaceutical Benefits Advisory Committee (PBAC), an independent statutory body, makes recommendations to the Minister for Health about which medicines should and should not be subsidized on the Pharmaceutical Benefits Scheme (PBS). In order for medicines to be considered by PBAC, they need to have been given market approval by the Therapeutic Goods Administration (TGA). If the PBAC makes a positive recommendation, the government decides whether or not to fund the medicine and prices are then negotiated by Department of Health. In addition to PBS-funded medicines, the Federal Government has a special programme for funding trastuzumab (Herceptin) for metastatic breast cancer. This programme was established in 2006 in response to pressure from patients and advocacy groups and was estimated to cost tax-payers $470 million to treat approximately 6300 women over the three years from 2006 to 2009 (MacKenzie et al. 2008 .
Hospital, district, or state Drug and Therapeutics Committees (DTCs) (with state government funding) play a substantial role in providing access to cancer medicines not listed on the PBS through their formularies or through their provisions for BIndividual Patient Use^(IPU). Private insurance companies also sometimes contribute to the costs of cancer medicines not listed on the PBS, and pharmaceutical companies may provide Bfree^or subsidized access to cancer medicines through various kinds of Bcompassionate accessp rogrammes or on an individual basis. Under these arrangements, between 2011 and 2012, nine pharmaceutical companies in Australia provided twenty-eight different cancer medicines to 4,748 patients of which 85 per cent were fully funded (Deloitte Access Economics 2013). Patients can also access medicines (or at least have the chance of doing so) through clinical trials or pay the entire cost of the medicines themselves.
The Senate Inquiry Into Access to Cancer Medicines in Australia
In December 2014, independent Senator for South Australia, Nick Xenophon, successfully put forward a motion to the Australian Senate for an inquiry into the availability of new, innovative, and specialist cancer drugs in Australia. This was prompted by concerns that Australians were not getting timely access to innovative cancer medicines, particularly when compared to other countries.
The matter was referred to the Senate Community Affairs Reference Committee for investigation, with a focus on scrutinizing: 1) the timing of access to cancer medicines and their affordability, 2) the operation of the Pharmaceutical Benefits Advisory Committee and the Pharmaceutical Benefits Scheme in relation to such drugs, including the impact of delays in the approvals process for Australian patients, and 3) the impact of existing processes on the quality of care available to Australian cancer patients.
The inquiry received 205 submissions from a broad spectrum of stakeholders including individual consumers and patients, consumer advocacy groups, physicians, pharmaceutical companies, and government. A public hearing was also held on 20 April 2015. The final report was published on 17 September 2015. It was divided into chapters that examined the timeliness of access to new medicines, affordable access and costeffectiveness assessment, the impact of delayed access to cancer medicines, and alternative access models.
Contested Notions of Bthe Good^in Debates About Access to Cancer Medicines in Australia
In our analysis of the Senate Report, we identified four key notions of Bthe good^when it comes to the funding of high cost cancer medicines, which we refer to as: 1) biomedical innovation, 2) equity, 3) compassion and choice, and 4) system sustainability.
Biomedical Innovation
Some contributors to the Senate Inquiry focused their attention on advantages of innovative cancer treatments-particularly targeted therapies-over traditional cytotoxic chemotherapy. They argued that innovative cancer medicines not only increase life expectancy more than older drugs but also offer more convenient and less toxic treatment regimens, which enable cancer patients to lead more comfortable and productive lives. They observed that this, in turn, makes health systems more efficient by reducing reliance on other healthcare resources and has broader societal benefits by, for example, making cancer patients more economically productive. They were therefore critical of what they perceived to be a lack of consideration of indirect health costs in existing health technology assessment processes. The pharmaceutical company Novo Nordisk, for example, complained that only direct health costs could be included in most submissions to the PBAC, with no account of loss of productivity, impact on carer's income, and increase in welfare/disability payments: Despite the economic evaluation (i.e., the cost effectiveness analysis) being mandated to take a Bsocietal perspective,^only direct health care costs can be included as the base case for the majority of submissions. That is, no account can be made of Bindirect costs,^including loss of productivity, impact of time/wages lost by carers, increase in welfare / disability payments, etc. (Senate Community Affairs Reference Committee 2015, 44)
Those with a focus on promoting innovation also expressed concern about PBAC's demand that new innovative medicines must be shown to be more cost-effective than off-patent medicines. More specifically, they complained about the government's price-disclosure policies, which were considered to artificially drive down prices of off-patent medicines, making it virtually impossible to demonstrate the relative value of some new medicines and, in some cases, leading to the decision not to pursue reimbursement at all. Finally, PBAC was seen to be insufficiently sensitive to the technical and financial challenges associated with generating data for new cancer medicines. Overall, PBAC's perceived epistemic and economic conservatism was seen to block timely access to important innovative cancer medicines, leading to Australian patients being worse off than patients in other developed countries.
Equity
For some contributors to the Inquiry, the greatest problem with the existing system of regulating and funding medicines is that large groups of patients are discriminated against, through no fault of their own. The drug development process, the nature of pharmaceutical markets, and current health technology assessment processes were all seen to work against particular patientsmost notably those suffering from rare cancers, paediatric cancer patients, and cancer patients who live in rural and remote regions.
With regard to patients with rare diseases, it was noted that it is difficult to conduct adequately powered clinical trials to demonstrate the safety and efficacy of new therapies and that there is usually little financial incentive for industry to develop drugs that affect few people. These neglected patients were seen to be left to their own devices to search for ad hoc solutions to their health problems, such as seeking compassionate access from drug sponsors or looking for clinical trials for which they are eligible.
Paediatric patients were seen to be equally disadvantaged because even the most common cancers in adults affect only a small proportion of children, and cancer medicines often have to be tested in adults before children, leading to inequities where children cannot get subsidized access to the same drugs that adults can even if they are suffering from the same type of cancer. Dr Christopher Frazer, the Chair of Australian and New Zealand Children's Haematology/Oncology Group, summarized this challenge:
The problem is, to get to that PBS approval, the data is almost never going to be available to prove clinical and cost-effectiveness in extremely small patient groups, and the economic incentive to try and collect the data is not going to be available. The drug company is going to say: BLet's apply for a listing for breast cancer.^They are not going to be worried about a rare liver tumour in children. At the moment in our system we have to beg our hospital executives to pay for these drugs, and they may or may not approve it. (Senate Community Affairs Reference Committee 2015, 77) In their submission to the Inquiry, the BKids Cancer Project^gave the example of clofarabine, which is used to treat acute lymphoblastic leukaemia. Because the medicine is subsidized on the PBS for adults only, the annual cost of treatment for children can reach $100,000 whereas for adults the out-of-pocket cost is only $37.
In addition to noting the particular inadequacies of PBAC processes for disadvantaged groups, some complained about the additional burden imposed on these groups by the uncertainty around so-called Balternative^pathways to access, such as through clinical trials, hospital formularies, or industry compassionate access programmes. It was noted that all of these alternatives are unpredictable and conditional on eligibility. If patients cannot gain access via these mechanisms, they must grapple with the additional emotional stress of finding ways to pay for a medicine that may help them. As one consumer noted:
So in addition to the emotional stress they are under, these people need to try and fund treatments to get well. These treatments can be extremely expensive and many can't afford them. Access to medicines should not be dictated by the type of cancer someone has, nor the income they earn. These people do not put their hands up to get cancer, they are a victim of circumstance and should not be discriminated against just because their disease is rare. (Senate Community Affairs Reference Committee 2015, 78) Importantly, when disadvantaged groups were discussed, the source of the problem was inevitably seen to be the government's Bdeficient^subsidization scheme. In other words, there was convergence between those who viewed Bthe good^as an innovation-friendly system and those whose view of Bthe good^centred on equity. This view was captured by a young consumer who argued that the Bbig drug companies need help from the government to find better ways to help kids get new drugs^(Senate Community Affairs Reference Committee 2015, 81).
Compassion and Choice
For some stakeholders contributing to the inquiry, the primary focus was on the need to be compassionate and to ensure that desperate patients should be empowered to access cancer medicines that may extend or improve their quality of their life. Quality of life was framed in terms of personal experiences and values, including Btime with family,^Bhope,^Bdignity,^Bvulnerability,â nd Bempowerment.^This view was perhaps best articulated by Mr Richard Vines, the Executive Chair of Rare Cancers Australia:
This issue is not just about money; it is about compassion. It is about hope. It is about quality of life. It is about quantity of life. It is about time with children. It is about time with family. And it is about dignity and grace at the end of life. It is about how we as a community care for those amongst us who are most vulnerable. Perhaps, most critically, it is also about how we empower our cancer physicians to care for us. They are the ones we trust with our lives, no-one else. (Senate Community Affairs Reference Committee 2015, 51)
For those with this orientation, economic considerations-particularly reliance on quality-adjusted life years (QALYs) and comparative cost-effectiveness measures-were deemed to have too prominent a place in PBAC decision-making. For instance, it was considered important to give cancer patients a choice to try innovative treatments if there is even a small chance of them improving their length or quality of life, as one cancer patient noted:
… I also think that we patients should be given a choice. It should be my choice to try other drugs, as if I am forced to continue to take the medication I am currently taking, I will also have to face some realities of a diminished quality of life, progression in my disease which could introduce new risks and even a shorter life span. (Senate Community Affairs Reference Committee 2015, 65-66) It was also seen to be important to acknowledge that some cancer patients may have a higher propensity for risk-taking than others and that this should be appreciated by those making regulatory and funding decisions. This was the view put forward by a representative of the Cure Brain Cancer Foundation:
In the vast majority of cases, people living with brain cancer have a very short time to live. Therefore, their risk propensity is extremely high in many cases-far higher than their doctors sometimes realise. They are quite prepared to take extreme risks when they need to if they think they have hope of a cure. (Senate Community Affairs Reference Committee 2015, 67)
Sustainability
The final major theme that we identified in the Senate Report was the perceived importance of making efficient use of existing resources so that the maximum number of people can be treated with an allocated set of funds and in order to ensure the future viability of the Pharmaceutical Benefits Scheme. Stakeholders with this orientation argued that yielding to demands by industry and patient advocates for greater and earlier access to cancer medicines without adjustments to pricing would create an enormous economic burden for Australian society. These concerns were summed up well in a comment from PBAC:
It is highly likely that earlier access to cancer drugs will greatly increase cost to the community if the mechanism by which earlier access is granted involves acceptance of prices that result in much higher estimates of cost-effectiveness. (Senate Community Affai rs Reference Committee 2015, 31) Statistics were cited showing the opportunity costs associated with funding cancer medicines. For example, the Department of Health reported that while cancerrelated prescriptions accounted for only 1 per cent of all PBS prescriptions between 2013-14, they account for 16 per cent of pharmaceutical spending. The Department also observed that the cost of agreeing to fund all cancer medicine submitted for consideration at only one meeting of the Pharmaceutical Benefits Advisory Committee would have cost the health system over half a billion dollars.
A rigorous system of health technology assessment, together with government pricing policies that Bcontinue to put pressure on medicine price[s]^were seen by this group of stakeholders as powerful counterbalances to unrestrained market forces. The price-disclosure mechanism for post-patent medicines mentioned previously, for example, was seen as providing an important means of creating savings to support a sustainable public insurance scheme.
The Society of Hospital Pharmacists of Australia argued for maintaining a rigid and formal approach to assessing cancer medicines, using as a warning the U.K. Cancer Drug Fund experience (established to Benhanceâ ccess to cancer medicines) which resulted in the United Kingdom paying higher prices than the rest of Europe for cancer medicines, diversion of funds away from other treatments, and overspending that has resulted in delisting many cancer medicines. The U.K.'s National Institute for Health and Care Excellence added to these concerns in its submission, noting that the U.K. Cancer Drugs Fund had resulted in less pricing pressure on pharmaceutical companies, an increase in the number of drugs licensed on the basis of preliminary data, and significant uncertainty around how much the drugs are really worth. In addition, it was noted that many innovative cancer medicines demonstrate only marginal improvements and are priced much higher than equally innovative drugs to treat other life-threatening diseases.
Inquiry Conclusions and Recommendations
In its conclusion, the committee responsible for the Senate Inquiry reiterated that cancer is an area of high unmet need, and that cancer Bpatients face significant financial hardship.^Furthermore they concluded that Bdelays in access to new and innovative cancer medicines^led to real and measurable harm to patients. While the committee recognized that the challenges faced by cancer patients wanting to access medicines were similar to those faced by patients diagnosed with a range of chronic and less common diseases, they also considered cancer to be unique since the Bvast majority of cancer patients do not have time on their side.T he Pharmaceutical Benefits Scheme was seen by the committee as the most equitable mechanism for providing affordable access to cancer medicines when compared to alternatives such as clinical trials and compassionate access programmes and highlighted a number of ways in which the operation of the Therapeutic Goods Administration and Pharmaceutical Benefits Advisory Committee might be enhanced. This included calling for more streamlined and flexible processes to Baddress concerns regarding the responsiveness of the current registration system^such as: more flexible evidence requirements, greater formal emphasis on qualityof-life considerations, permitting non-industry sponsors to seek registration of new indications, and increased involvement of patients and clinicians in decisionmaking processes to capture community expectations about moral and ethical considerations. Importantly the committee believed there was a need to consider a range of avenues to address Bdemand for early access to new medicines,^including the potential interim use of the Life Saving Drugs Program (a programme used to provide expensive life-saving medicines for rare life-threatening conditions) to provide Bgovernment funded compassionate access^for patients with uncommon cancers, and enhancing the operation of the existing managed access programme (where drugs that address a clear clinical need are recommended at a price warranted by existing albeit uncertain evidence, pending collection of further data that may warrant a higher price) to make it a more attractive avenue for companies to utilize.
Discussion
The Power of Rhetoric in Debates About Access to Cancer Medicines Taken together, the conclusions and recommendations listed above appear to take for granted the Bgoods^of compassion and choice, equity, and innovation, with far less explicit regard for mechanisms to ensure the sustainability of the Pharmaceutical Benefits Scheme in Australia. While the sustainability challenge was acknowledged in the conclusion and recommendations of the Senate Report, if it had been given more weight in deriving the Senate Report's recommendations we would have expected much more to be said about specific measures to curtail high prices of cancer medicines in Australia-medicines that often provide relatively little benefit.
One possible explanation for this lacuna is the rhetorical force of the various Bgoods^that support enhanced access to new cancer medicines, such as compassion and choice, equity, and innovation. What these Bgoods^all have in common is that they tap into fundamental existential concerns: compassion combats the fear of being neglected or facing death and the fear of being excluded from society; equity combats Benvy^-the judgement and feeling that others are being treated better then oneself (Mooney 2000b) ; while innovation is the means through which hope emerges. In this way, the arguments for reform draw strongly upon pathos as a mode of persuasion, arousing deeply embedded existential hopes and fears (McCormack 2014) . These concerns and hopes are, in turn, fuelled by media reports of patients who have had dramatic responses to new cancer treatments and patients who have been denied access to potentially life-saving medicines because they are too expensive, as well as by well-meaning attempts by clinicians and other patient advocates to empower cancer patients to advocate for access to new medicines. Concerns about sustainability, in contrast, appeal to more abstract notions such as procedural and distributive justice. And since sustainability aims at the public interest rather than the individual, its benefits may be less visible and more difficult to Bsell^through popular media, especially if it means denying desperate patients access to medicines they believe may help them.
Another possible explanation could be that Australia already tends to do quite well at curtailing prices of cancer medicines relative to other countries, and therefore the issue of sustainability is less urgent within the Australian setting than it might be in other settings. A recent study showed that the median Australian price of a patented cancer medicine was US$2,741 for a month of treatment, in comparison to the price in the United States of US$8,694 (Goldstein et al. 2016) . While Australia paid more than the United Kingdom, India, and South Africa, the affordability of these medicines was higher in Australia than in these other countries. At the same time, an IMS Institute report suggests that Australian cancer patients do not suffer as a result of spending less and in fact achieve amongst the best results across six cancer types when compared to nine developed countries (Australia came first in three of the six cancer types)(IMS Institute 2014). It may be, therefore, that the authors of the report simply did not believe that sustainability was the primary issue at stake as Australia fares relatively well in terms of what it pays for medicines and corresponding health outcomes. Perhaps this is why the terms of reference for the inquiry focused primarily on the impact that current approval processes have on cancer patients now, rather than the potential impact on the health system, and therefore society, that may result from any changes.
It seems unlikely, however, that it was solely Australia's relative economic advantages that led to sustainability being overlooked in the Senate report. After all, health funding is a major political issue in Australia, and the Pharmaceutical Benefits Scheme is a frequent target of calls for reduced spending. It seems likely, therefore, that that the lacuna we observed was, at least in part, driven by deeply held-and deliberately stokedfears and hopes that are often associated with cancer.
While it is important to respond to existential concerns through the pursuit of compassion, choice, equity, and innovation, unrestrained appeals to associated deepseated emotions has the potential to lead to the suspension of reasoned deliberation about the relative merits of different medical interventions given their cost. This might not matter if the only consequence was that pressure was put on PBAC to make relatively uncontroversial changes, such as greater efficiency, consumer engagement, and transparency. It is a different matter altogether, however, if rhetoric and appeals to emotion compel PBAC to relax its usual standards regarding evidence of safety, efficacy, effectiveness, and its usual (albeit informal) thresholds for what it considers to be cost-effective when it comes to cancer medicines and to ignore the potential flow on effect such precedents may have for funding of medicines as a whole.
For this reason, it seems highly significant that the Senate Report and its recommendations focused on the need for earlier and greater (Baccelerated^) access to cancer medicines, (including the possibility of expanding the Life Saving Drugs Program to provide access to treatment for patients with uncommon cancers) while not conducting an in-depth investigation of the potential epistemic, ethical, and economic challenges of doing so. It is beyond the scope of this article to discuss the potential downsides of accelerated access in detail (for more detailed consideration, see Pace et al. 2017 and Lewis, Kerridge, and Lipworth 2015) . These downsides may, however, include: potential threats to patient safety and greater pressure on healthcare budgets if standards of safety, efficacy, and cost-effectiveness are overridden, undermining of regulatory systems and of evidence-based medicine, and (paradoxically) a stifling of genuine pharmaceutical innovation if a signal is sent to the pharmaceutical industry that society is willing to pay high prices and accept high uncertainty for medicines that provide for most people only marginal benefit.
Therefore while finding ways to Bimprove^access to innovative cancer medicines may indeed improve health outcomes for specific individuals, it may also lead to harm and to the wasting of limited health resources, as well as compromising rather than stimulating innovation. We have mentioned above how Australia already seems to perform quite well on the international stage when it comes to cancer health outcomes, and the belief that directing more money at new drugs in the name of Bcompassion,^Bchoice,^Bequity,^and Binnovationŵ ill necessarily lead to significantly better health outcomes does not hold up to scrutiny.
Concluding Thoughts
None of this is to argue against the judicious acceleration of access to medicines when there are good ethical, scientific, clinical, or physiological rationales for doing so, with a corresponding increase in the amount of attention paid to patients' values and money devoted to the funding of cancer medicines. What is apparent, however, is that a natural reaction to existential fears that confront society every time cancer is discussed can lead to undermining the system of checks and balances that have evolved over decades to manage the complex interplay between the need for evidence, the need to spend tax-payers' money judiciously, and the need to ensure that patients have access to health technologies with an acceptable risk-benefit ratio. How exactly to balance these considerations will be a topic of ongoing debate. While this debate will play out differently in different jurisdictions, we believe that all health systems could benefit from deconstructing the implied values in demands for Benhanced access^to cancer medicines, in a manner that informs the identification of more nuanced questions and therefore solutions.
We believe the most important questions that arise from this work are: What do we really mean by Bcompassion^and Bequity^in the context of cancer care? Are we in fact being Bcompassionate^and reducing inequities when we provide access to treatments that are, for all intents and purposes, experimental or that provide only marginal benefits? What do we actually mean by Binnovation^when many novel products are only marginally beneficial compared to existing alternatives? What are we willing to sacrifice as a society in terms of evidence standards, safety, and opportunity cost, for hope of better cancer outcomes in the future? And, should Bsustainability^be reframed so that it is not (only) about affordability but also about solidarity, justice, and protection of precious societal resources-goods that may be at least as important as compassion, equity, and innovation.
